Healthcare RCM Outsourcing Market in the US 2015-2019, New Report Launched

Report forecast the Healthcare RCM Outsourcing market in the US to grow at a CAGR of 15.51 percent over the period 2014-2019.

Healthcare service providers have long since deployed automated systems to address RCM processes. Legacy IT applications have outdated technology platforms that lack the advanced functionality needed to address new models for reimbursement or RCM. The complex processes of medical billing and collections resulted in gaps and inefficiencies that have led to loss in revenue. Considering the issues pertaining to revenue cycle processes and workflows, hospitals and health systems considered the outsourcing option for RCM service. The outsourcing of RCM services ensures maximum collections in the face of growing challenges and also reduces the potential revenue leakage for different RCM processes.

This Report Covers the Healthcare RCM Outsourcing market in the US is categorized into three segments: Front-end Services, Middle Services, and Back-end Services.

Healthcare RCM Outsourcing Market in the US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the landscape of the Healthcare RCM Outsourcing Market in the US and its growth prospects in the coming years. The report also includes a discussion on the key vendors operating in this market.

Key Vendors

• Conifer Health Solutions
• Emdeon
• MedAssets
• Parallon Business Solutions
• The SSI Group

Other Prominent Vendors

• Adreima
• Alleviant
• Avadynehealth
• Cardon Outreach
• FirstSource Solutions
• Health Systems Management Network
• Medirevv
• Precyse Solutions
• Recondo Technology
• SourceMedical
• Sutherland Global Services
• T-Systems
• Xerox

Market Driver

• Need to Meet Government Compliances
• For a full, detailed list, view our report

Market Challenge

• Selecting the Right Vendors
• For a full, detailed list, view our report

Market Trend

• Emergence of Analytics Solution
• For a full, detailed list, view our report

Key Questions Answered in this Report

• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Spanning over 65 pages, “Healthcare RCM Outsourcing Market in the US 2015-2019” report covering the Executive Summary, List of Abbreviations, Scope of the Report, Market Research Methodology, Introduction, Market Landscape, Market Segmentation by Services, uying Criteria, Market Growth Drivers, Drivers and their Impact, Market Challenges, Impact of Drivers and Challenges, Market Trends, Trends and their Impact, Vendor Landscape, Key Vendor Analysis. The report covered companies are - Conifer Health Solutions, Emdeon, MedAssets, Parallon Business Solutions, The SSI Group, Adreima, Alleviant, Avadynehealth, Cardon Outreach, FirstSource Solutions, Health Systems Management Network, Medirevv, Precyse Solutions, Recondo Technology,SourceMedical, Sutherland Global Services, T-Systems, Xerox 

Know more about this report at – http://mrr.cm/4UP

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare

China Insulin Market Review to 2018 - Increasing Focus on R&D Investments, New Report Launched

China Insulin Market Review to 2018 - Increasing Focus on R&D Investments report presents a comprehensive analysis of market size by volume and value of major types of insulin consumed in China. The report entails the segment wise market share analysis and company profiles of major players in the insulin market in China. The future analysis of the market has also been discussed in the report.

The prevalence of diabetes in China has grown from 1% per capita in 1980 to more than 12% in 2013, making it the country with the most diabetic cases globally. In addition to 148 million people with pre-diabetes, 98.4 million people were diagnosed with diabetes in the country in 2013. In the near future, 6%-7% of those with pre-diabetes will be added to the existing diabetic population. Additionally, 40% of the youth aged 18-29 are potential diabetes patients with a high risk of stroke, heart disease and renal failure. Thus, the disease has become a matter of grave concern for the country and its wellbeing in the future.

Diabetes has reached catastrophic levels in China. According to the International Diabetes Federation, 98.4 million people in China were diagnosed as diabetic in 2013, representing the country with the largest diabetes cases in the world. The undiagnosed diabetic cases in China amounted to ~ million in 2013. Adding significantly to the mortality rate of China, nearly ~ million people died from diabetes in the country during the same year.

The consumption of insulin, the basis of diabetes care, is gaining momentum in China. With revenue generation of USD ~ million in 2013, China’s insulin market has grown at a tremendous pace since 2008. Although, low awareness relating to diabetes care in the country is a major cause hindering treatment and diagnosis of diabetes, the scenario is witnessing change. With a CAGR of ~% during 2008-2013, the demand for insulin has been underpinned by growing diabetic population, gradually increasing knowledge regarding diabetes care and the rising affluence of the masses. In terms of volume, it is estimated that nearly ~ thousand of million units (tMU) of insulin was consumed in 2013, which has been growing at ~% CAGR from 2008 to 2013.

The insulin market in China is evolving rapidly. Analog insulin has become the preferred choice of the diabetic population in the country not only on account of efficacy, but also the fact that people are being able to afford the high costs that are carried with analog insulin replacement therapy. The market for human insulin in China is being substituted by analog insulin every year. In 2008, the Chinese insulin market was largely composed of human formulations with ~% share, which was reduced to ~% in 2013. The analog insulin market has grown considerably during the same period, registering an impressive CAGR of ~%. In 2013, the value addition to the overall insulin market by the sale of analog insulin was USD ~ million, whereas that of human insulin was USD ~ million.

The government of China is actively involved in resisting the problems related to the increasing prevalence of diabetes in the country. Through the initiation of healthcare reforms, the government has significantly contributed to the growth of the insulin market in China. Medical insurance, drug supply security, medical-service provision and public health services are some of the initiatives undertaken by the government. The government has also collaborated with several leading insulin companies for spreading awareness via campaigns and free diagnostic services.

The rising epidemic of diabetes in China and its economic wellbeing has attracted the major insulin enterprises operating globally. Companies such as Novo Nordisk, Eli Lilly and Sanofi Aventis capture a large proportion of the market, whereas domestic players including Tonghua Dongbao and Shanghai Fosun Pharmaceutical share a small fraction of the Chinese insulin market. Since analog insulin is emerging as the favored choice amongst the diabetic patients in the country, the vast and superior portfolio offered by the foreign multinationals has assisted them in constricting the market. These companies are also carrying out extensive R&D within the country in order to understand the local trends and supplying corresponding solutions.

Key Topics Covered in the Report

• The market size of China insulin market in terms of value and volume
• Market segmentation by insulin replacement therapy and types of insulin
• Government regulation and support schemes for China’s insulin market
• Trends and developments in China insulin market
• Growth drivers of China insulin market
• Market share of major players in the insulin market in China
• Market share of major players by types of insulin
• Company profiles of major players in China’s insulin market
• Future outlook and projections of the insulin market in China
• Macroeconomic factors affecting the insulin market in China

Spanning over 80 pages, “China Insulin Market Review to 2018 - Increasing Focus on R&D Investments” report covering the Asia Pacific Insulin Market Introduction, China Insulin Market Introduction, China Insulin Market Size by Sales Value and Volume, 2008-2013, China Insulin Market Segmentation, 2008-2013, Government Regulations and Support Schemes for China Insulin Market, Trends and Developments in China Insulin Market, Growth Drivers in China Insulin Market, Market Shares of Major Companies in China Insulin Market, Company Profiles of major Players in China Insulin Market, China Insulin Market Future Outlook and Projections, 2014-2018, Macroeconomic Factors in China Insulin Market, 2008-2018, Appendix. The report covered companies are - Novo Nordisk, Eli Lilly, Sanofi Aventis, BJ Ganli Pharmaceutical, Tonghua Dongbao

Know more about this report at – http://mrr.cm/4UN

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare

Nonalcoholic Steatohepatitis (NASH) – Novel Drug Candidates, New Report Launched

The Competitive Intelligence report about Nonalcoholic Steatohepatitis (NASH) - Novel Drug Candidates provides a competitor analysis in the development pipeline of novel therapeutics for treatment of NASH. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Nonalcoholic hepatosteatosis (NASH) is a common, serious chronic liver disease characterized by inflammation and excessive fat accumulation in the liver and may lead to progressive fibrosis, cirrhosis and liver failure. NASH is estimated to affect 10 to 20 percent of people in the developed world. There are currently no approved therapies to treat NASH.

NASH is similar to alcohol-induced steatohepatitis, and is associated with factors that cause an increase in oxidative stress and promote expression of proinflammatory cytokines. NASH is the most common cause of fibrosis and cirrhosis in patients with unexplained increased alanine aminotransferase.

Currently, the diagnosis of hepatic fibrosis is most commonly conducted by a liver biopsy. With magnetic resonance elastography, in use in the United States since 2009 and in Japan since 2012, it has become possible to measure the relative stiffness of liver tissues in a non-invasive manner.

The report provides a compilation of active projects in research and development for treatment of NASH including small molecules, antibodies, peptides and RNAi. Competitor projects are listed in a tabular format providing information on:

• Drug Codes
• Target / Mechanism of Action
• Class of Compound
• Company
• Product Category
• Indication,
• R&D Stage.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Spanning over 25 pages, “Competitor Analysis: Nonalcoholic Steatohepatitis (NASH) – Novel Drug Candidates” report covering the Clinical Stage Drug Candidates for Treatment of NASH, Preclinical Stage Drug Candidates for Treatment of NASH.

Know more about this report at – http://mrr.cm/43C

Find all Biotechnology Reports at: http://www.marketresearchreports.com/biotechnology

Recombinant Coagulation Factors 2015: Maturation of recombinant clotting factor pipeline and emergence of gene therapy and alternative procoagulants, New Report Launched

A Pipeline Landscape Analysis and Comparative Assessment of Key Players:

This report provides an update of recombinant coagulation factors used for controlling bleeding of hemophilia A and B and other bleeding disorders. 2013 sales figures and 2014 nine-month sales data are analyzed to evaluate commercial development of the market under the light of a strong pipeline and entry of new competitor products into the market. The profiles of drug candidates in development are presented in details not only for recombinant coagulation factors VIII, IX and VII, but also for emerging alternative procoagulants, gene therapeutics and immune tolerance inducing agents.

The competitve landscape of classical recombinant coagulation factors and of new emerging treatment modalities of hemophilia and other severe bleeding orders is analyzed. The emergence of new treatment modalities brings many new stakeholders to the field of hemophilia. Among them are the established hemophilia portofolio companies, but also new entrants from Big Pharma and Big Biotech, specialty pharmaceutical companies, biosimilar companies, and new technology providers as half-life prolongation technologies are no longer in the focus of major interest.

A short- to mid-term outlook into the field is provided and the trends driving the future of this therapeutic segment are identified and described. The data are presented, analyzed and assessed in a comprehensive manner by an experienced author with an independent view writing the fifth edition of this report series.

Benefits from the report:

• Development of product sales and recombinant coagulation factors market
• Sales performance of newly launched recombinant coagulation factors
• Drug profiles for all relevant classical as well a semerging developments
• Technologies, constructs and players in the gene therapy field of hemophilia
• Alternative procoagulants: approaches, profiles, competitive advantages
• Comparative analysis of key product features of new coagulation factors
• Corporate profiles of all relevant stakeholders including deals and pipelines
• Pipeline and technology trends

Spanning over 210 pages, “Recombinant Coagulation Factors 2015: Maturation of recombinant clotting factor pipeline and emergence of gene therapy and alternative procoagulants” report covering the Executive Summary, Recombinant Coagulation Factor Markets, Pipeline Update of Recombinant Coagulation Factors, Competitive Landscape Analysis of Recombinant Coagulation Factors, Stakeholder Profiles, Strategic Analysis, References, ADDENDUM: Development and Approval Timelines. The report covered companies are - Alnylam Pharmaceuticals, Alphamab, Alteogen, Amarna Therapeutics, Apitope, Arcturus Therapeutics, Aryogen, AstraZeneca, Baxter, Bayer HealthCare Pharmaceuticals, Biogen Idec, Biotest, Catalyst Biosciences

Know more about this report at – http://mrr.cm/43y

Find all Therapeutic Reports at: http://www.marketresearchreports.com/therapeutic

Therapeutic Class Overview : Moderate to Severe Pain: Novel Abuse Deterrent Formulation Technologies and Emergence of Novel Mechanisms in the Management of Pain, New Report Launched

Pain is the leading cause of disability in the US, affecting more than cancer, diabetes and heart disease combined. Current analgesics for persistent pain are relatively ineffective, are associated with significant adverse effects or abuse liability, and do not reduce pain in all treated individuals. Opioids (e.g., morphine, codeine, oxycodone) are currently one of the most potent groups of analgesics used clinically, with prescriptions increasing by 50% over the past 10 years for chronic, non-cancer pain. However, there is clear evidence that as opioid prescription rate rise, there is a corresponding increase in opioid overdose deaths, misuse and addiction. These adverse effects are attributed to the opioid agonist effects on central opioid receptors—causing dependence, tolerance, sedation, and respiratory depression.

Non-steroidal and steroidal anti-inflammatory drugs have serious side effects such as gastric erosions, ulcer formation, bleeding, hypersensitivity reactions, cardiovascular toxicity, renal toxicity, and hepatotoxicity. In addition, they are also not peripherally selective thereby causing a range of central adverse effects. Over the past 20 years, most analgesic development activities have been limited to the reformulation of opioids, production of new cyclooxygenase (COX) inhibitors, amine reuptake inhibitors and anticonvulsants, and introduction of topical local anesthetics—all of these act on well-established targets. A significant unmet need exists in the emergence of novel mechanism which will avoid the current NSAIDS side effects with improved efficacy. Several newer mechanisms currently being explored will have the ability to replace opioids in the treatment of acute and chronic moderate to severe pain.

Globally, pain is one of the important therapy areas with a market size of over $50b in 2013, and is expected to grow at 10%. The recent patent expiry of Cymbalta and Lyrica (2018) will have significant impact on the overall pain market size in the near future. However, several pipeline molecules are emerging to fill this gap. The importance of abuse deterrent labeling in the formulations can be better understood from FDA’s non-approval of oxycontin generics in 2013. The revised labeling with abuse deterrence has protected Purdue’s oxycontin revenue slide from its generization.

In the wake of abusive potential of opioids drugs reported all across the US, FDA recently drafted guidance for  evaluation and labeling of opioids formulations based on their ability to reduce its abusive potential (tier 1 to 4). Despite the process being in nascent stage, several specialty companies have already ventured into the development of abuse deterrent formulations to reap benefits in the near future.

In this report, we have discussed a number of novel delivery technologies employed in the formulation of abuse deterrent product, technologies employed in enhancing patient compliances and emerging novel mechanisms in the management of pain. Renewed interest on pain therapy is vision as recently Biogen Idec acquired Convergence’s CNV1014802 (Nav 1.7 sodium channel blocker) to expand its neuropathic pain portfolio and we believe several such acquisitions will happen in the near term.

Spanning over 64 pages, “Therapeutic Class Overview : Moderate to Severe Pain: Novel Abuse Deterrent Formulation Technologies and Emergence of Novel Mechanisms in the Management of Pain” report covering the Management of Pain, FDA Schedule for controlled substances and advantage of Schedule III over II, FDA Guidelines for the development of abuse deterrent formulations, Abuse deterrent Technology Platforms employed in marketed drugs and pipeline, Pipeline analysis of Novel Mechasim in Pain Therapy, Late stage pipeline developments in neuropathic pain.

Know more about this report at – http://mrr.cm/43j

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare  

U.S. Orthopedic Biomaterials Market - 2015, New Report Launched

The fastest growing segments involve stem cells, namely the segments for stem cell bone grafts and concentrated bone marrow. The products within these markets offer the greatest regenerative potential for healing bone.

Orthopedic biomaterial products compete with products that are more established and less expensive. Thus, clinical evidence is often an important deciding factor for orthopedic biomaterials over conventional forms of therapy especially in regards to reimbursement. However, the promise seen in some products such as bone marrow concentrate generates growth despite a lack of clinical evidence and reimbursement.

The U.S. orthopedic biomaterials market includes bone graft substitutes, growth factors, orthopedic stem cells, cell therapy, hyaluronic acid viscosupplementation, cartilage repair and machined bone allografts.

Report Contents:

• Competitor Analysis
• Identified Strategic Opportunities
• Indepth Procedure Volumes
• Market Overview by Segment
• Trend Analysis by Segment
• Market Drivers & Limiters
• Mergers & Acquisitions
• Customer Feedback and Market Monitoring

Main Segments Covered:

• U.S. Orthopedic Biomaterials Procedures
• Orthopedic Bone Graft Substitute Market
• Orthopedic Growth Factor Market
• Orthopedic Stem Cell Market
• Orthopedic Cell Therapy Market
• Orthopedic Hyaluronic Acid Viscosupplementation Market
• Orthopedic Cartilage Repair Market
• Spinal Machined Bone Allograft Market

Report Highlights:

• A wide range of devices/treatments covered in the report focused around regenerative and resorbable orthopedic options
• Complementary products such as PRP (provides growth factor) and BMC (provides stem cells) used in conjunction with bone graft substitutes. Allows the graft to compete with growth factor and stem cell bone grafts
• Highlights trend towards demineralized bone matrices and synthetics
• Competitive analysis broken down for each type: allograft, DBM and synthetics
• A wide range of devices/treatments covered in the report focused around regenerative and resorbable orthopedic options
• Cartilage repair market includes two new segments: juvenile particulated allograft (Zimmer’s DeNovo) and microfracture adjunct (Arthrex’s BioCartilage)

Spanning over 288 pages “U.S. Orthopedic Biomaterials Market - 2015” report Covering Executive Summary, Research Methodology, U.S. Orthopedic Biomaterials Market Overview, Procedure Numbers, Orthopedic Bone Graft Substitute Market, Orthopedic Growth Factor Market, Orthopedic Stem Cell Market, Orthopedic Cell Therapy Market, Orthopedic Hyaluronic Acid Viscosupplementation Market, Orthopedic Cartilage Repair Market, Spinal Machined Bone Allograft Market. This report Covered 22 Companies - Aastrom, Allosource, Anika Therapeutics, Artrhex, Baxter, Biomet, Bioventus, DePuy Synthes, Exactech, Ferring Pharmaceuticals, Fidia Pharmaceuticals, Genzyme, Harvest, Integra LifeSciences, MTF, Medtronic, NuVasive, Orthofix, RTI Surgical, Stryker, Wright Medical, Zimmer.

Know more about this report at – http://mrr.cm/43g

Find all Biotechnology Reports at: http://www.marketresearchreports.com/biotechnology

U.S. Laparoscopic Device Market - 2015, New Report Launched

Growth in laparoscopic device market segments will exceed procedure number growth rates due to the continuing development of higher-priced multifunctional devices. The direct energy, ultrasonic, and closure device segments will all benefit substantially from this trend. Laparoscopic procedures are not only cosmetically beneficial for the patient, but have clinical benefits as well. A minimally invasive approach results in faster patient recovery, potentially shorter hospital stays, fewer post-operative complications and overall reduced surgical risk.

Value Added Services

Value-added services provide an opportunity for companies looking to increase their bottom line in markets that are saturated with alternative products. These optional extras will allow companies to ensure that their products maintain a competitive advantage over other devices in the market.

Popularity of Disposable Products in the U.S.

Despite being the more expensive option, disposable products are significantly more popular than their reusable alternatives. Reposable tissue management systems are also significantly more popular than their fully reusable options. This trend is driven by a combination of factors, the primary one being concerns about the sterility of reusable devices.

The U.S. market for laparoscopic devices includes laparoscopes, access devices, hand instruments, insufflation devices, suction-irrigation devices, direct energy devices, ultrasonic energy devices, hand-assisted devices, closure devices, and gastric bands, powered morcellators, and female sterilization devices.

Report Contents:

• Competitor Analysis
• Identified Strategic Opportunities
• Indepth Procedure Volumes
• Market Overview by Segment
• Trend Analysis by Segment
• Market Drivers & Limiters
• Mergers & Acquisitions
• Customer Feedback and Market Monitoring

Main Markets Covered:

• Laparoscope Market
• Access Device Market
• Hand Instrument Market
• Insufflation Device Market
• Suction-Irrigation Device Market
• Direct Energy Device Market
• Ultrasonic Device Market
• Hand-Assisted Device Market
• Closure Device Market
• Gastric Band Market
• Powered Morcellator Market
• Female Sterilization Device Market

U.S. Laparoscopic Devices Market Emerging Technologies Covered:

• Robotics in Laparoscopic Surgery
• Surgical Smoke Evacuation Systems
• Gastric Banding for Adolescents and Lower Body Mass Index
• Transcervical Female Sterilizationhnologies

Procedures segmented by:

State, outpatient and inpatient procedures, outpatient and inpatient

Procedures covered:

• Cholecystectomy Procedures
• Nephrectomy Procedures
• Female Sterilization Procedures
• Bariatric Surgery Procedures
• Anti-Reflux Procedures
• Bowel Resection Procedures
• Appendectomy Procedures
• Hernia Repair Procedures
• Hysterectomy Procedures
• Single Port Surgeries Procedures
• Other Laparoscopic Procedures

Report Highlights:

• Includes in depth procedural analysis that compares two important trends

a) For each of the included procedures, quantitatively compares open procedures versus laparoscopic procedures

b) For each of the included procedures, quantitatively compares outpatient and inpatient procedures

• Includes 12 of the most popular laparoscopic procedures included
• Each procedure segmented into outpatient and inpatient datasets
• For both outpatient and inpatient data, number of procedures using laparoscopic approach compared to number of procedures utilizing open/other approaches
• Detailed analysis of procedures performed by state
• Forecasting of procedures, with a focus on how the proportion of laparoscopic procedures will change over time
• Detailed competitive analysis that shows market shares for each segment within most chapters
• Descriptive and qualitative information for the market drivers and limiters for each segment

Spanning over 341 pages “U.S. Laparoscopic Device Market - 2015” report Covering Executive Summary, Research Methodology, U.S. Laparoscopic Device Market Overview, Procedure Numbers, Laparoscope Market, Access Device Market, Hand Instrument Market, Insufflation Device Market, Suction-Irrigation Device Market, Direct Energy Device Market, Ultrasonic Device Market, Hand-Assisted Device Market, Closure Device Market, Gastric Band Market, Powered Morcellator Market, Female Sterilization Device Market. This report Covered 17 Companies - Apollo Endosurgery, Applied Medical, B. Braun Aesculap, Blue Endo, C. R. Bard, CareFusion, ConMed, Cooper Surgical, Covidien, Ethicon, Integra LifeSciences, Karl Storz, LiNA Medical, Microline Surgical, Olympus, Richard Wolf, Stryker.

Know more about this report at – http://mrr.cm/43Y

Find all Medical Devices Reports at: http://www.marketresearchreports.com/medical-devices